- Home
- MGRX vs QNTM Comparison
MGRX vs QNTM Comparison
Compare MGRX & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- QNTM
- Stock Information
- Founded
- MGRX 2021
- QNTM 1998
- Country
- MGRX United States
- QNTM Canada
- Employees
- MGRX N/A
- QNTM N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- QNTM
- Sector
- MGRX Technology
- QNTM
- Exchange
- MGRX Nasdaq
- QNTM NYSE
- Market Cap
- MGRX 8.1M
- QNTM 8.7M
- IPO Year
- MGRX 2023
- QNTM N/A
- Fundamental
- Price
- MGRX $2.10
- QNTM $6.91
- Analyst Decision
- MGRX
- QNTM
- Analyst Count
- MGRX 0
- QNTM 0
- Target Price
- MGRX N/A
- QNTM N/A
- AVG Volume (30 Days)
- MGRX 223.6K
- QNTM 919.6K
- Earning Date
- MGRX 05-14-2025
- QNTM 05-06-2025
- Dividend Yield
- MGRX N/A
- QNTM N/A
- EPS Growth
- MGRX N/A
- QNTM N/A
- EPS
- MGRX N/A
- QNTM N/A
- Revenue
- MGRX $615,873.00
- QNTM N/A
- Revenue This Year
- MGRX N/A
- QNTM N/A
- Revenue Next Year
- MGRX N/A
- QNTM N/A
- P/E Ratio
- MGRX N/A
- QNTM N/A
- Revenue Growth
- MGRX N/A
- QNTM N/A
- 52 Week Low
- MGRX $1.49
- QNTM $2.70
- 52 Week High
- MGRX $16.80
- QNTM $33.80
- Technical
- Relative Strength Index (RSI)
- MGRX 43.32
- QNTM 53.04
- Support Level
- MGRX $1.63
- QNTM $5.91
- Resistance Level
- MGRX $2.85
- QNTM $6.43
- Average True Range (ATR)
- MGRX 0.37
- QNTM 0.72
- MACD
- MGRX 0.11
- QNTM -0.05
- Stochastic Oscillator
- MGRX 44.24
- QNTM 56.19
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.